Series A financing round lays foundation for international growth of digital cancer therapeutics Mika
Berlin/Lausanne/Barcelona/Munich, April 2022 – Berlin-based digital health company Fosanis, the developer of Mika, Germany’s first prescription DTx for all oncological indications, closed a series A funding round of more than 10 million EUR. Besides existing shareholders such as Ananda Impact Ventures, three new investors joined in the latest financing round: lead investor Swiss company Debiopharm […]
Read More